GRAIL and Quest Diagnostics Announce Collaboration to Support Galleri, First-of-Kind Multi-Cancer Early Detection Blood Test
February 23 2021 - 8:30AM
Business Wire
-- Quest Diagnostics to Provide Blood Specimen
Collection for Galleri Through its Patient Service Centers and
Mobile Phlebotomists --
GRAIL, Inc., a healthcare company whose mission is to detect
cancer early, when it can be cured, today announced an agreement
with Quest Diagnostics (NYSE: DGX), the leading provider of
diagnostic information services, to provide phlebotomy services to
support Galleri™, GRAIL’s multi-cancer early detection blood
test.
Quest Diagnostics maintains approximately 2,200 patient service
centers and, through its ExamOne business, 5,000 mobile
phlebotomists with expertise in at-home visits. Quest’s phlebotomy
network will help provide blood specimen collection for Galleri in
the United States once the test becomes available this year.
“Today, the majority of cancers go undetected until too late
when outcomes are often deadly, and we believe Galleri could offer
a unique and potentially life-saving solution by finding multiple
types of cancers earlier,” said Dr. Joshua Ofman, chief medical
officer and head of external affairs at GRAIL. “We are pleased to
work with Quest and are very encouraged by the interest in Galleri.
Our agreement with Quest will help us support convenient access to
blood collection for patients and healthcare providers.”
“Quest Diagnostics is committed to providing the broadest access
to diagnostic innovation. That includes multi-cancer early
detection, an important area of oncology diagnostics with potential
to radically improve cancer screening, monitoring, and treatment,”
said Kristie M. Dolan, vice president and general manager, Oncology
Clinical Franchise, for Quest Diagnostics. “Galleri is a pioneer in
early detection innovation, and we are eager to support GRAIL’s
efforts to make it accessible to patients across the United
States.”
In January, GRAIL announced it expects to introduce Galleri in
the second quarter of 2021. The blood test, which will be
prescription only, will be available initially through partner
health systems, medical practices, and self-insured employers.
An earlier version of Galleri demonstrated the ability to detect
more than 50 types of cancers — over 45 of which lack recommended
screening tests today — with a low false positive rate of less than
1%. When a cancer signal is detected, Galleri can determine the
location of the cancer signal with high accuracy, all from a single
blood draw. Galleri is intended to be used alongside standard of
care screenings.
Galleri is available under investigational use in PATHFINDER,
GRAIL’s prospective, interventional study evaluating the
implementation of Galleri in clinical practice. Galleri is also
expected to be offered to eligible patients in the United Kingdom
(UK) later this year as part of a partnership with the UK National
Health Service to support its Long Term Plan for earlier cancer
diagnoses in an effort to transform cancer outcomes.
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer
early, when it can be cured. GRAIL is focused on saving lives and
improving health by pioneering new technologies for early cancer
detection. The company is using the power of next-generation
sequencing, population-scale clinical studies, and state-of-the-art
computer science and data science to overcome one of medicine’s
greatest challenges with Galleri™, GRAIL’s multi-cancer early
detection test. An earlier version of Galleri demonstrated the
ability to detect more than 50 types of cancers — over 45 of which
lack recommended screening tests today in the U.S. — with a low
false positive rate of less than 1%. GRAIL is headquartered in
Menlo Park, California, with locations in Washington, D.C., North
Carolina, and the United Kingdom. It is supported by leading global
investors and pharmaceutical, technology, and healthcare
companies.
About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve
health outcomes. Derived from the world's largest database of
clinical lab results, our diagnostic insights reveal new avenues to
identify and treat disease, inspire healthy behaviors and improve
health care management. Quest annually serves one in three adult
Americans and half the physicians and hospitals in the United
States, and our 50,000 employees understand that, in the right
hands and with the right context, our diagnostic insights can
inspire actions that transform lives. www.QuestDiagnostics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210223005677/en/
GRAIL Contacts Corporate Communications Kelsey Grossman
pr@grail.com Investor Relations John Craighead ir@grail.com
QUEST Contact Media Relations Jennifer Petrella
mediacontact@questdiagnostics.com
Quest Diagnostics (NYSE:DGX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Quest Diagnostics (NYSE:DGX)
Historical Stock Chart
From Apr 2023 to Apr 2024